We demonstrated that a blood-based biomarker panel including plasma Aβ42/Aβ40, APOE status and age could be employed in the pre-screening phase of Alzheimer’s disease clinical trial recruitment to reduce future costs associated with Aβ PET screening. Here, APOE is linked to Alzheimer disease.